NCT02195440View on ClinicalTrials.gov

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Hepatitis C Virus-infected Cirrhosis
Interventions
DRUG

PRI-724

10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.

Trial Locations (1)

Unknown

Tokyo metropolitan Komagome Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

Prism Pharma Co., Ltd.

INDUSTRY

collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Komagome Hospital

OTHER